Sugi Predict

Sugi Predict / Compounds / SCHEMBL4830604

SCHEMBL4830604

SCHEMBL4830604

C[S+]([O-])c1ncc2cc(Br)c(=O)n(C3CCCC3)c2n1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCND1 P24385 15/20 0.55
▸ CDK2 P24941 15/20 0.55
▸ CDK4 P11802 9/20 0.55
▸ CCNA2 P20248 5/20 0.55
▸ CCND3 P30281 4/20 0.53
▸ CCND2 P30279 3/20 0.53
▸ FGFR1 P11362 3/20 0.48
▸ FGFR2 P21802 3/20 0.48
▸ FGFR4 P22455 3/20 0.48
▸ FGFR3 P22607 3/20 0.48
▸ CCNA1 P78396 2/20 0.48
▸ PIK3CA P42336 2/20 0.41
▸ CCNE1 P24864 10/20 0.40
▸ CDK6 Q00534 8/20 0.40
▸ CCNT1 O60563 3/20 0.40
▸ CDK9 P50750 3/20 0.40
▸ NUAK1 O60285 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153370 1.00 CCND1 (0.55) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL4833696 0.99 CCND1 (0.54) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL22200529 0.95 CCND1 (0.49) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL4828668 0.87 CDK2 (0.53) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL4826681 0.87 CCND1 (0.48) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL29507751 0.85 CDK2 (0.40) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL4835866 0.85 CCND1 (0.54) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL31073291 0.83 CDK2 (0.56) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL22015971 0.83 NUAK1 (0.56) CCND1CDK2CDK4CCNA2CCND3
SCHEMBL29507954 0.83 NUAK1 (0.56) CCND1CDK2CDK4CCNA2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324872-A1 CDK2/4/6 Inhibitors PFIZER INC. (US) 2022-10-13 — — US disclosed
US-11396512-B2 CDK2/4/6 inhibitors PFIZER INC. (US) 2022-07-26 — — US disclosed
EP-3497103-B1 PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS PFIZER (US) 2021-05-05 — — EP disclosed
US-20200392142-A1 CDK2/4/6 Inhibitors PFIZER INC. (US) 2020-12-17 — — US disclosed
US-10800783-B2 CDK2/4/6 inhibitors PFIZER INC. (US) 2020-10-13 — — US disclosed
EP-3497103-A1 PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS Pfizer Inc (US) 2019-06-19 — — EP disclosed
US-20190135817-A1 CDK2/4/6 Inhibitors PFIZER INC. (US) 2019-05-09 — — US disclosed
US-10233188-B2 CDK2/4/6 inhibitors PFIZER INC. (US) 2019-03-19 — — US disclosed
WO-2018033815-A1 PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS PFIZER INC. (US) 2018-02-22 — — WO disclosed
WO-2018033815-A1 PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS PFIZER INC. (US) 2018-02-22 — — WO disclosed
US-7208489-B2 Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example WARNER-LAMBERT COMPANY (US) 2007-04-24 — — US disclosed
EP-1718645-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES Warner-Lambert Company LLC (US) 2006-11-08 — — EP disclosed
EP-1470124-B1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES WARNER LAMBERT CO (US) 2005-12-28 — — EP disclosed
WO-2005082903-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2005-09-09 — — WO disclosed
US-6936612-B2 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones WARNER-LAMBERT COMPANY (US) 2005-08-30 — — US disclosed
US-20050182078-A1 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones WARNER-LAMBERT COMPANY, LLC 2005-08-18 — — US disclosed
US-20050137214-A1 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones WARNER-LAMBERT COMPANY 2005-06-23 — — US disclosed
EP-1470124-A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES Warner-Lambert Company LLC (US) 2004-10-27 — — EP disclosed
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones BARVIAN MARK (US) 2003-08-07 — — US disclosed
WO-2003062236-A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324872-A1 CDK2/4/6 Inhibitors CDK2, CDK6, CDK20 CCND1 40/4885CDK2 1/4885CDK4 5/4885
US-20200392142-A1 CDK2/4/6 Inhibitors CDK2, CDK6, CDK20 CCND1 39/4885CDK2 1/4885CDK4 6/4885
US-20030149001-A1 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones CDK4, CDK2, CDK1 CCND1 27/4885CDK2 2/4885CDK4 1/4885
US-11396512-B2 CDK2/4/6 inhibitors CDK2, CDK6, CDK20 CCND1 40/4885CDK2 1/4885CDK4 5/4885
US-10800783-B2 CDK2/4/6 inhibitors CDK2, CDK6, CDK20 CCND1 40/4885CDK2 1/4885CDK4 5/4885
US-20190135817-A1 CDK2/4/6 Inhibitors CDK2, CDK6, CDK20 CCND1 40/4885CDK2 1/4885CDK4 5/4885
US-20050182078-A1 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones CDK2, CDK4, CDK1 CCND1 18/4885CDK2 1/4885CDK4 2/4885
US-20050137214-A1 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones CDK4, CDK2, CDK3 CCND1 34/4885CDK2 2/4885CDK4 1/4885
US-10233188-B2 CDK2/4/6 inhibitors CDK2, CDK6, CDK20 CCND1 40/4885CDK2 1/4885CDK4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.